Generic Name and Formulations:
Fenofibric acid (as choline fenofibrate) 45mg, 135mg; del-rel caps.
Indications for TRILIPIX:
Adjunct to diet to reduce TG in severe hypertriglyceridemia, and to reduce elevated LDL-C, Total-C, TG, and apo B, and to increase HDL-C in primary hypercholesterolemia or mixed dyslipidemia.
Limitations Of use:
Fenofibrate (at a dose equivalent to 135mg of Trilipix) did not reduce coronary heart disease morbidity and mortality in 2 controlled trials of patients with type 2 diabetes.
Swallow whole. Primary hypercholesterolemia or mixed dyslipidemia: 135mg once daily. Hypertriglyceridemia: 45–135mg once daily. Titrate at 4–8week intervals; max 135mg/day. Mild-to-moderate renal impairment: initially 45mg once daily.
Severe renal impairment (including on dialysis). Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver function abnormalities. Gallbladder disease. Nursing mothers.
The effect on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established. Patients with diabetes, renal failure, hypothyroidism, elderly: increased risk of myopathy. Monitor liver function; discontinue if LFTs >3XULN persist. Renal impairment: monitor renal function. Discontinue if markedly elevated CPK levels, myopathy, gallstones, hypersensitivity reactions, or severely depressed HDL-C levels occur (do not reinitiate). Monitor RBC and WBC counts during first 12 months of therapy. Pregnancy (Cat.C).
Increased risk of myopathy/rhabdomyolysis with concomitant statins, colchicine. Potentiates warfarin (monitor PT/INR). Separate dosing of bile acid sequestrants by at least 4–6 hours. Risk of nephrotoxicity with cyclosporine, tacrolimus.
Abnormal LFTs, increased AST/ALT, increased CPK, rhinitis; myopathy, rhabdomyolysis, hematological changes (eg, hgb, hct), increased serum creatinine, cholelithiasis, pancreatitis, hypersensitivity reactions (may be severe).
Hepatic; 99% protein bound.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline